Google
BIVI — BIOVIE INC (Healthcare >> Biotechnology)
BIVI FAQ
What is BIVI's ROE?
BIOVIE INC reports a Return on Equity (ROE) of -127.61%.
What is BIVI's dividend yield?
BIOVIE INC offers a dividend yield of 0.00%.
What is BIVI's Deepscope Quality Score?
Deepscope rates BIVI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIVI?
Deepscope's AI Timing Score for BIVI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIVI belong to?
BIOVIE INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.67
Price
0.00
(0.00%)
Day Change
|
|
|---|
BIVI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.67 |
| PBV / Sector |
0.81 / 4.71
GREAT
|
| Earning Per Share | -2.62 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.17 M
GREAT
|
| Average 1W Daily Value |
0.23 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:12 |
| Symbol | BIVI |
| Name | BIOVIE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 7.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 12.71 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 680 W. Nye Lane, Carson City, NV, United States, 89703
Phone: 775 888 3162
Website: https://bioviepharma.com
Sector: Healthcare >> Biotechnology
Description: BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
